We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Rapid Diagnostic Tool to Revolutionize Diagnosis of Tick-Borne Diseases

By LabMedica International staff writers
Posted on 11 Oct 2022

Tick-borne illnesses have ballooned in recent years. More...

Tick-borne pathogens can be passed to humans by the bite of infected ticks. Those ticks can carry bacteria, viruses or parasites. Now, a team of biomedical engineers is working to ramp up and reimagine how medical professionals diagnose tick-borne infections such as Lyme disease.

Scientists at West Virginia University (Morgantown, WV, USA) are developing a tool that more quickly detects tick-borne diseases via a blood sample on a single chip. Their model aims to detect disease within one to two weeks after the onset of an infection, whereas existing approaches rely on a symptom-based questionnaire – which might ask if a person has a fever or a rash – and tests that aren’t reliable until at least a few weeks after infection. Their project was recently awarded USD 1.2 million as a joint initiative between the National Science Foundation and the National Institutes of Health.

The research will involve cross-disciplinary use of microfluidics, sensors and machine-learning. Those factors will enable improved diagnosis of tick-borne infections via a non-invasive, affordable, quick and user-friendly tool. After collecting a blood sample from a patient, the tool will analyze the cells. All cells have a set of dielectric properties like permittivity and conductivity that are unique for cell membrane and cell cytoplasm. Those properties are heavily dependent on the state of the cell, such as whether it is normal or abnormal.

The unique properties depend on the shape and size of the cell; if the membrane is rough, smooth or leaky; and what is happening within the cell interior. Once a few drops of blood enter the device, an electric field will sort them based on the state, size and shape of the cells. The sorted cells will have a baseline value of capacitance that will show up by the sensor and thus we can conclude the type of infection. What makes the project more unique is its ability to detect multiple tick-borne infections at once, and in a timely fashion.

“Most tests available currently are symptom-based and symptoms develop four to six weeks after a tick bite,” said Soumya Srivastava, assistant professor at the Benjamin M. Statler College of Engineering and Mineral Resources, who is leading the team. “Our platform can detect these diseases early on, within one to two weeks, in under 30 minutes using a portable diagnostic tool. If successful, this tool may be useful for a variety of health applications beyond tick-borne diseases. Rapid detection could reduce the risk of hospitalization, doctor’s visits and prevent the disease from progressing into a chronic, life-long condition.”

Related Links:
West Virginia University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Gold Member
Platelet Function Analyzer
PL-12
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
image Credit: iStock

Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer

Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.